ARTICLE | Company News

HCV stocks fall after Gilead's discount signal

February 5, 2015 2:24 AM UTC

HCV stocks took a hit on Wednesday after Gilead Sciences Inc. (NASDAQ:GILD) said it will provide larger discounts in 2015 than investors were anticipating on its Harvoni ledipasvir/ sofosbuvir and Sovaldi sofosbuvir.

The disclosure came in Gilead's earnings call Tuesday after market close, when Gilead said it expects an adjusted gross to net of 46% for its HCV drugs, more than double the 22% rate in 2014 (see BioCentury Extra, Feb. 3). ...